Gallen consensus panel meeting, 48% of the panellists agreed that they would offer olaparib to patients with BC having a somatic BRCA1 pathogenic variant but no hereditary germline mutation, whereas 47% of the panellists mentioned that they would not (31). The gene discussed is BRCA1; the disease is breast cancer.